CONGENITAL PARVOVIRUS B19 INFECTION

CONGENITAL PARVOVIRUS B19 INFECTION was reported 1 times

CONGENITAL PARVOVIRUS B19 INFECTION is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Hydrolytic Lysosomal Glucocerebroside-specific Enzyme [EPC] 1 0.0001
1 Calcium [EPC] 1 0.0000
2 Platelet Aggregation Inhibitor [EPC] 1 0.0000
3 Nonsteroidal Anti-inflammatory Drug [EPC] 1 0.0000